Spero Therapeutics, Inc.
SPROHealthcareNASDAQBiotechnology · Last scanned Jul 22, 2026
Scan Results
Daily timeframeSpero Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on identifying and developing novel treatments for multi-drug resistant (MDR) bacterial infections and rare diseases in. With a market capitalization of $79.9M, it sits in micro-cap territory. The company's product candidates include Tebipenem HBr (tebipenem pivoxil hydrobromide), an oral carbapenem-class antibiotic to treat complicated urinary tract infections, including pyelonephritis for adult patients, which has completed second Phase 3 trial.
Market Cap
$79.9M
Beta
1.49
P/E (TTM)
5.31
P/E (Fwd)
-1.24
EPS (TTM)
$0.26
EPS (Fwd)
$-1.11
ROE
35.1%
ROA
13.0%
Cash
$56.1M
Total Debt
$2.5M
Free CF
$13.2M
52W Change
-42.7%
Annual Financials
Cash vs Debt
Where SPRO stands vs its 150-day and 200-day moving averages
As of the July 15, 2026 close, SPRO finished 30.61% below its 150-day moving average ($2.45) and 29.46% below its 200-day moving average ($2.41). This snapshot is end-of-day data shown with a five-trading-day delay on the free plan; Premium members see readings from the latest close.
Is SPRO overbought or oversold?
At the July 15, 2026 close, SPRO's RSI(14) was 30.1, in neutral territory (between 30 and 70). The MACD histogram was negative, so short-term momentum leaned bearish at that close. These readings are historical, refresh daily after market close, and are not investment advice.
Spero Therapeutics, Inc. holds $56.1M in cash against $2.5M in total debt, giving it a net cash position. This means the company could theoretically pay off all its debt and still have cash remaining. The company generates $13.2M in free cash flow annually, which funds everything from R&D to shareholder returns without needing external financing. Return on equity stands at 35.1%, which is exceptionally high for the sector. ROE measures how effectively a company uses shareholder capital to generate profits. Return on assets of 13.0% further supports the picture of efficient asset utilization. Revenue has grown from $48.6M (2022) to $59.6M (2025), reflecting a 23% increase over the period.
The strong cash position relative to debt provides a financial cushion that reduces balance sheet risk. These risk factors are not exhaustive — macroeconomic shifts, regulatory changes, and competitive dynamics can all influence Spero Therapeutics, Inc.'s trajectory.